Catalent today published its Corporate Responsibility (CR) Report for fiscal year 2020. The report covers environmental, social, and governance topics relevant to Catalent’s business.

The partnership will see Catalent use its proprietary OptiGel® DR technology to encapsulate OmeGo, HBC’s unique fish oil derived from sustainable, traceable, and fresh Norwegian Atlantic salmon.

The facility will accommodate Catalent’s new commercial-scale plasmid DNA (pDNA) manufacturing and will provide the opportunity for the immediate growth of Catalent’s pDNA service offering.

Catalent and Stirling Ultracold today announced a partnership whereby Stirling Ultracold becomes the preferred provider of ULT storage across Catalent’s multiple business units.

AavantiBio and Catalent today announced a partnership to support the development and manufacturing of AavantiBio’s gene therapies, including its lead program in Friedreich’s Ataxia (FA).

Catalent today announced that it has made an investment to expand capabilities at its clinical supply services facility in Philadelphia to support sponsors developing cell and gene therapies.

Catalent has completed the expansion of two new suites at its biologics drug substance development and manufacturing facility in Madison, Wisconsin, and has now commenced work on customer programs.

Catalent announced that its clinical supply experts will be participating in upcoming Global Clinical Supplies Group (GCSG) events, discussing cell and gene therapy supply chains, direct-to-patient (DTP) services, and just-in-time delivery models.

Moderna and Catalent today announced the expansion of their strategic partnership to dedicate a new high-speed vial filling line for the manufacture of the Moderna COVID-19 Vaccine at Catalent’s facility in Bloomington, Indiana.